PARP1 and neoplasm: We performed TWAS of clinical outcome and lab-derived phenotypes from the central regulators of ferroptosis, cuproptosis, and parthanatos and identified strong associations between PARP1 and neoplasms (Fig. S3A) and platelet traits (Fig. S3B).